Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
This article was originally published in The Pink Sheet Daily
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.
You may also be interested in...
Also, agency tells AEterna Zentaris its growth hormone deficiency drug Macrilen requires a new confirmatory trial, and privately held Spriaso announces FDA acceptance of NDA for Rinotuss12, a solid oral dose cough/cold product combining codeine and chlorpheniramine.
As companies present their third quarter earnings they discuss the drugs that they’ve launched over the last quarter – some have had success right out of the gate, while others hope to build momentum, albeit more slowly.
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.